Product Description
The OkuStim therapy was developed for patients with degenerative retinal diseases such as retinitis pigmentosa. You can use it to slow down the progression of the disease. The core of the therapy is the OkuStim system, with which you stimulate your retina independently and at home with weak electrical currents. (Sourced from: https://okuvision.de/en/)
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Okuvision
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TES-GPS | N/A |
Not yet recruiting |
Glaucoma, Open-Angle|Low Tension Glaucoma|Exfoliation Syndrome |
2027-06-01 |
|
| TES-NIS2021 | N/A |
Completed |
Retinitis Pigmentosa |
2022-08-19 |
|
| TES/RP | N/A |
Withdrawn |
Retinitis Pigmentosa |
2020-12-01 |
|
| IRB#15-478 | N/A |
Unknown status |
Amblyopia |
2020-08-01 |